| Market Cap | 175.20M | P/E | 65.80 | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -3.64M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -1.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | - |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -9.00% |
| Recommedations | - | Quick Ratio | 0.10 | Shares Outstanding | 14.30M | 52W Low Chg | 14.00% |
| Insider Own | - | ROA | - | Shares Float | 6.79M | Beta | - |
| Inst Own | 122.65% | ROE | - | Shares Shorted/Prior | 13.37K/9.62K | Price | 9.87 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 181,697 | Target Price | - |
| Oper. Margin | - | Earnings Date | - | Volume | 13,488 | Change | 2.92% |
Frazier Lifesciences Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or related business combination with one or more businesses or entities in the biotechnology sector. The company was incorporated in 2020 and is based in Seattle, Washington.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP | 10% Owner 10% Owner | Nov 02 | Buy | 10.08 | 847,062 | 8,538,385 | 1,211,582 | 11/04/22 |